| European Federation of Internal Medicine

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News

Type: News Feed

Human medicines European public assessment report (EPAR): Tuyory, tocilizumab, Date of authorisation: 27/04/2026, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 21 August 2026 - 14:34

Human medicines European public assessment report (EPAR): Tuyory, tocilizumab, Date of authorisation: 27/04/2026, Revision: 2, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Tuyory, tocilizumab, Date of authorisation: 27/04/2026, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation: 24/06/2021, Revision: 9, Status: Authorised

Submitted by Anonymous (not verified) on 21 August 2026 - 14:24

Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation: 24/06/2021, Revision: 9, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation: 24/06/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Eylea, aflibercept, Date of authorisation: 21/11/2012, Revision: 40, Status: Authorised

Submitted by Anonymous (not verified) on 21 August 2026 - 14:02

Human medicines European public assessment report (EPAR): Eylea, aflibercept, Date of authorisation: 21/11/2012, Revision: 40, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Eylea, aflibercept, Date of authorisation: 21/11/2012, Revision: 40, Status: Authorised

Orphan designation: 2-(2-Chlorobenzylidene)hydrazinecarboximidamide acetate Treatment of Charcot-Marie-Tooth disease, 14/12/2015 Positive

Submitted by Anonymous (not verified) on 21 August 2026 - 14:00

Orphan designation: 2-(2-Chlorobenzylidene)hydrazinecarboximidamide acetate Treatment of Charcot-Marie-Tooth disease, 14/12/2015 Positive

Read more about Orphan designation: 2-(2-Chlorobenzylidene)hydrazinecarboximidamide acetate Treatment of Charcot-Marie-Tooth disease, 14/12/2015 Positive

Human medicines European public assessment report (EPAR): Isembyld, apitegromab, Status: Application withdrawn

Submitted by Anonymous (not verified) on 21 August 2026 - 14:00

Human medicines European public assessment report (EPAR): Isembyld, apitegromab, Status: Application withdrawn

Read more about Human medicines European public assessment report (EPAR): Isembyld, apitegromab, Status: Application withdrawn

Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive

Submitted by Anonymous (not verified) on 21 August 2026 - 14:00

Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive

Read more about Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive

Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 10, Status: Authorised

Submitted by Anonymous (not verified) on 21 August 2026 - 14:00

Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 10, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 10, Status: Authorised

Orphan designation: Icerguastat acetate Treatment of amyotrophic lateral sclerosis, 16/05/2022 Positive

Submitted by Anonymous (not verified) on 21 August 2026 - 13:59

Orphan designation: Icerguastat acetate Treatment of amyotrophic lateral sclerosis, 16/05/2022 Positive

Read more about Orphan designation: Icerguastat acetate Treatment of amyotrophic lateral sclerosis, 16/05/2022 Positive

Orphan designation: chenodeoxycholic acid Treatment of inborn errors in primary bile acid synthesis, 16/12/2014 Positive

Submitted by Anonymous (not verified) on 21 August 2026 - 13:58

Orphan designation: chenodeoxycholic acid Treatment of inborn errors in primary bile acid synthesis, 16/12/2014 Positive

Read more about Orphan designation: chenodeoxycholic acid Treatment of inborn errors in primary bile acid synthesis, 16/12/2014 Positive

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Human medicines European public assessment report (EPAR): Tuyory, tocilizumab, Date of authorisation: 27/04/2026, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation: 24/06/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Eylea, aflibercept, Date of authorisation: 21/11/2012, Revision: 40, Status: Authorised

Orphan designation: 2-(2-Chlorobenzylidene)hydrazinecarboximidamide acetate Treatment of Charcot-Marie-Tooth disease, 14/12/2015 Positive

Human medicines European public assessment report (EPAR): Isembyld, apitegromab, Status: Application withdrawn

Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive

Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 10, Status: Authorised

Orphan designation: Icerguastat acetate Treatment of amyotrophic lateral sclerosis, 16/05/2022 Positive

Orphan designation: chenodeoxycholic acid Treatment of inborn errors in primary bile acid synthesis, 16/12/2014 Positive

Newsletters

Latest Newsletters

You are here

Newsletters

Latest Newsletters